CN109394777A - Application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug - Google Patents
Application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug Download PDFInfo
- Publication number
- CN109394777A CN109394777A CN201811522812.7A CN201811522812A CN109394777A CN 109394777 A CN109394777 A CN 109394777A CN 201811522812 A CN201811522812 A CN 201811522812A CN 109394777 A CN109394777 A CN 109394777A
- Authority
- CN
- China
- Prior art keywords
- anoectochilus roxburghii
- osteoarthritis
- roxburghii glycosides
- cartilage
- macrophage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug.Anoectochilus roxburghii glycosides can reduce damage of the inflammatory factor IL-1 β to cartilage cell, directly protection cartilage cell；Can also targeted inhibition control the polarized NF- κ B signal access of macrophage, lower macrophage M1 polarization level, promote M2 polarization level, thus reduce NF- κ B relevant inflammatory factors release, protect cartilage cell in vivo and in vitro.In addition, anoectochilus roxburghii glycosides can also cartilage cell's vigor caused by the inflammatory microenvironment by mitigating osteoarthritis inhibit and apoptosis, play the role of indirect protection cartilage, to treatment and slow down osteoarthritis.The present invention for more fully understand osteoarthritis pathologic process and from now on to treatment osteoarthritis drugs exploitation provide new thinking and reference.
Description
Technical field
The present invention relates to field of medicaments, and in particular to application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug.
Background technique
Osteoarthritis (osteoarthritis, OA) is a kind of common chronic exercise systemic disease, is apt to occur in old female
Property knee joint, arthralgia can be caused and then lead to deformity.As a kind of common chronic bone, muscle systems disease, OA
Pathogenesis is not fully understood, it is known that mechanism be related to joint surface wear, arthritis, cartilage degeneration, bony structures
Remodeling, synovial membrane inflammation and spur are formed.Other factors include the hair that aging, obesity and genetic predisposition also facilitate osteoarthritis
It is raw.The treatment of OA includes conservative therapy and operative treatment, and conservative therapy such as takes non-steroidal anti-inflammatory drugs (NSAID) can respite
Pain, however such drug may cause the side effects such as gastric ulcer.Operative treatment mainly has Arthroscopic debridement, high-order fibula
Osteotomy and joint replacement etc., but surgery cost is relatively high and there are certain risks.Therefore, it is necessary to Bones and joints
Scorching this disease is further studied, and finds new treatment method.
Macrophage plays a significant role in inflammatory reaction, immune defense and tissue repair, in different microenvironments,
Macrophage can be different according to stimulant and polarization is M1 and M2 two types.M1 type (proinflammatory type) macrophage passes through bacterium
Lipopolysaccharides (LPS) and some cell factors such as interferon-γ (IFN-γ) and activate, their high expression proinflammatory cytokines are such as
IL-1 β, IL-6, tumor necrosis factor-alpha (TNF-α), IL-12, active oxygen radical (ROS) and nitric oxide synthetase
(iNOS).It is M2 type (anti-inflammatory type) that IL-4, IL-10 and IL-13, which can drive macrophage polarization, and M2 macrophage height expresses smart ammonia
Acid synthase -1 (Arg-1) and anti-inflammatory cytokines IL-10 cause anti-inflammatory and immunosupress reaction.In OA intrasynovial, macrophage
Under the action of inflammatory stimulus object, it is polarized to M1 type first, secretes inflammatory factor, promotes joint synovitis disease reaction, aggravates soft
Bone injury.Therefore inhibiting macrophage polarization is a potential important target spot for treating osteoarthritis.
Anoectochilus roxburghii glycosides (Kinenoside, Kin) are the ingredients of Chinese medicine roxburgh anoectochilus terminal bud (Anoectochilus roxburghii)
One of, adjustable immune response inhibits inflammation, protection blood vessel.Also have been reported that Kin can inhibit by adjusting NF- kB pathway
Osteoclast formation prevents bone-loss.Present invention firstly discovers that important glycoside chemical combination of the Kin as composition roxburgh anoectochilus terminal bud plant
Object can significantly inhibit macrophage M1 polarization, protect cartilage cell, play a role in treatment osteoarthritis.
Summary of the invention
The object of the present invention is to provide application of the anoectochilus roxburghii glycosides in treatment osteoarthritis drugs.
To achieve the above object, the technical scheme is that application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug.
Wherein, anoectochilus roxburghii glycosides are for treating the osteoarthritis because of caused by cartilage damage.
Wherein, osteoarthritis caused by cartilage damage caused by anoectochilus roxburghii glycosides are for treating because of macrophage M1 polarization.
Wherein, anoectochilus roxburghii glycosides are by inhibiting macrophage M1 polarization, directly protection cartilage cell, in treatment osteoarthritis
It plays a role.
Wherein, anoectochilus roxburghii glycosides lower the pole macrophage M1 by the polarized NF- κ B signal access of targeted inhibition macrophage
Change horizontal, promotion M2 polarization level, and then reduce the release of NF- κ B relevant inflammatory factors, cartilage cell is protected, to slow down and control
Treat osteoarthritis.
Wherein, anoectochilus roxburghii glycosides are used to slow down and treat because inflammatory factor IL-1 β is to bone caused by the damage of cartilage cell
Arthritis.
Wherein, damage of the anoectochilus roxburghii glycosides by mitigation inflammatory factor IL-1 β to cartilage cell, directly protection cartilage cell,
To slow down and treat osteoarthritis.
Wherein, anoectochilus roxburghii glycosides pass through the inhibition of cartilage cell's vigor caused by mitigating macrophage conditioned media and apoptosis,
Play the role of indirect protection cartilage.
Wherein, cartilage cell's vigor caused by inflammatory microenvironment of the anoectochilus roxburghii glycosides by mitigating osteoarthritis inhibits and withers
It dies, plays the role of indirect protection cartilage, to treat and slow down osteoarthritis.
Specifically, anoectochilus roxburghii glycosides can reduce damage of the inflammatory factor IL-1 β to cartilage cell, directly protection cartilage is thin
Born of the same parents；Can also targeted inhibition control the polarized NF- κ B signal access of macrophage, lower macrophage M1 polarization level, promote M2
Polarization level protects cartilage cell to reduce the release of NF- κ B relevant inflammatory factors in vivo and in vitro.In addition, with macrophage item
Part culture medium stimulates cartilage cell, and discovery anoectochilus roxburghii glycosides can reduce cartilage cell's vigor caused by conditioned medium and inhibit and wither
It dies, plays the role of indirect protection cartilage.Macrophage conditioned media simulates the inflammatory micro-loop of Human Osteoarthritis part
Border, the microenvironment can cause articular cartilage damage, aggravate the development of osteoarthritis, and therefore, anoectochilus roxburghii glycosides can reduce patient's inflammation
Property microenvironment caused by cartilage cell's vigor inhibit and apoptosis, play the role of indirect protection cartilage, to treatment and slow down bone
Arthritis.
The present invention is based on following experimental programs:
(1) Primary chondrocyte of rat is extracted, whether detection anoectochilus roxburghii glycosides directly mitigate cartilage cell caused by IL-1 β
Vigor inhibits and apoptosis；
(2) anoectochilus roxburghii glycosides are given while stimulating expression of macrophage polarizes, detect Macrophage Inflamatory with western blot
Relevant NF- κ B signal access probes into the expression of NF- κ B downstream relevant inflammatory factors and changes situation, and assessment anoectochilus roxburghii glycosides protection is soft
The effect of osteocyte；
(3) after anoectochilus roxburghii glycosides act on macrophage, the ingredient of its conditioned medium is detected.Then macrophage condition is used
Culture medium stimulates cartilage cell, and whether observation anoectochilus roxburghii glycosides mitigate cartilage cell's inflammatory reaction and apoptosis caused by inflammatory factor；
(4) verifying anoectochilus roxburghii glycosides could slow down cartilage degeneration in vivo, alleviate Bones and joints gap in animal experiments
It is narrow.
The present invention is based on following experimentations:
1. the extraction of Primary chondrocyte.Cartilage cell used in experiment is Primary chondrocyte, rather than cell line.It is former
Sterile principle should be followed by extracting for cartilage cell, first be digested 30 minutes with 0.25% EDTA pancreatin after taking out articular cartilage, with
It is stayed overnight afterwards with 0.2% Type Ⅱ collagen enzymic digestion.After culture 3-5 days, it is seen that apparent cartilage cell is adherent.
2. articular chondrocyte apoptosis analysis is dyed using Annexin V/PI.In Apoptosis early stage, membrane phospholipid acyl serine
By turning on one's side outward in adipose membrane, and Annexin V just can be with phosphatidylserine specific bond.Annexin V green
After fluorescence FITC label, it can be used to mark the cell of early apoptosis.Propidium iodide (Propidium Iodide, PI) is a kind of
Nucleic acid dye can only penetrate the cell membrane in apoptosis advanced stage and dead cell, therefore Annexin V and PI are used in combination, and can distinguish
The cell and dead cell in apoptosis advanced stage morning.
The identification of 3.M1/M2 type macrophage.We choose mark of the CD16/32 as M1 type macrophage, CD206 conduct
The mark of M2 type macrophage.The two mark expressions are detected using Laser Scanning Confocal Microscope, furthermore select fluidic cell point
Analyzer analyzes the variation of M1/M2 ratio after anoectochilus roxburghii glycosides stimulation.
4. the verifying of anoectochilus roxburghii glycosides Saving cortilage cartilage in osteoarthritis animal body.Osteoarthritis is big by cutting
Mouse anterior cruciate ligament of knee joint obtains.4th week after intraperitoneal injection of drugs obtains knee joint sample, by decalcification, takes off
The slice of HE and the fast green dyeing of sarranine are obtained after water, embedding, slice, dyeing.
Present invention firstly discloses the protection cartilage cell of anoectochilus roxburghii glycosides effect and its answering in treatment Osteoarthritis
With, and verifying anoectochilus roxburghii glycosides to adjust macrophage polarization is one of its mechanism.This statement has obtained lot of experimental data
Support, show that anoectochilus roxburghii glycosides have significant directly or indirectly cartilage cell's protective effect, and can be in future therapeutic Bones and joints
It plays a significant role in inflammation.
Detailed description of the invention
Fig. 1: the result figure that CCK-8 is tested in embodiment 1.1, display anoectochilus roxburghii glycosides different time points, various concentration are to soft
The influence of osteocyte vigor；
Fig. 2: the result figure that CCK-8 is tested in embodiment 1.2, display anoectochilus roxburghii glycosides are to the cartilage cell under IL-1 β effect
The influence of vigor；
Fig. 3: the result figure of embodiment 1.3, influence of the display anoectochilus roxburghii glycosides to the articular chondrocyte apoptosis under IL-1 β effect；
Wherein, A figure is flow cytometer showed result figure, and B figure is the statistical result for A figure.
Fig. 4: embodiment 2.1.1 result figure shows anoectochilus roxburghii glycosides on the polarized influence of macrophage；Wherein, A figure is M1 type
The immunofluorescence of macrophage mark CD16/32 and M2 type macrophage mark CD206 expression；B is fluidic cell point
Analyse result figure；C is the statistical chart for B figure.
Fig. 5: embodiment 2.1.2 result figure, display anoectochilus roxburghii glycosides believe NF- the κ B and MAPK in macrophage polarization process
The influence of number pathway protein expression；Wherein, A is the Western blot result figure of the key protein of NF- κ B access, and B is for A
The statistics histogram of band gray value in figure, C are the Western blot result figures of the key protein of MAPK access, and D is for C
The statistics histogram of band gray value in figure.
Fig. 6: embodiment 2.2.1 RT-qPCR testing result ratio, display anoectochilus roxburghii glycosides inhibit NF- κ B and MAPK signal
After access, downstream inflammatory factor expression is influenced.
Fig. 7: embodiment 2.2.2 CCK-8 experimental result picture, the CMC model after showing anoectochilus roxburghii glycosides stimulating expression of macrophage
Influence of the base to cartilage cell's vigor.
Fig. 8: the result figure of embodiment 3, display anoectochilus roxburghii glycosides are to the articular cartilage of osteoarthritis rat and joint space
It influences；Wherein, A figure is the X-ray piece of rat knee joints, and B figure is to the HE colored graph of knee joint slice, and C figure is to knee joint
Fast green (the Safranin O-fast green) colored graph of the sarranine of slice.
Specific embodiment
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.In addition, it should also be understood that, after reading the contents of the present invention, those skilled in the art can
To make various changes or modifications to the present invention, such equivalent forms equally fall within limited range of the present invention.
Present invention discover that anoectochilus roxburghii glycosides not only can directly protect cartilage cell, can also inhibit indirectly macrophage NF- κ B and
MAPK signal path activates and then inhibits macrophage M1 polarization, promotes M2 polarization, reduces NF- κ B and MAPK relevant inflammatory factors
It discharges and protects cartilage cell in vivo and in vitro.In addition, stimulating cartilage with different macrophage conditioned medias, roxburgh anoectochilus terminal bud is found
Glycosides can reduce the inhibition of cartilage cell's vigor caused by macrophage conditioned media and apoptosis, play the work of protection cartilage indirectly
With.
1 anoectochilus roxburghii glycosides of embodiment directly protect cartilage cell
1.1 by rat 3-4 for Primary chondrocyte, kind is in 96 orifice plates, 8000, every hole cell.3.125 μ g/ml~
Row CCK-8 is tested after 200 μ g/ml anoectochilus roxburghii glycosides are handled cartilage cell 2,24,48,72 hours, records the absorbance value of 450nm
(OD450)。
Fig. 1 is the result figure that CCK-8 is tested in embodiment 1.1, and Fig. 1 shows various concentration anoectochilus roxburghii glycosides in different time
Influence of the point to cartilage cell's vigor；Wherein, in each time point, the column of A~H respectively represents control (control), 3.125 μ
G/ml, 6.25 μ g/ml, 12.5 μ g/ml, 25 μ g/ml, 50 μ g/ml, 100 μ g/ml, 200 μ g/ml anoectochilus roxburghii glycosides processing cartilage are thin
Cell viability after born of the same parents.The results show that the 6.25 μ g/ml anoectochilus roxburghii glycosides of μ g/ml~25 are on cartilage cell's vigor without influence.
1.2 plant cartilage cell in 96 orifice plates, 8000, every hole cell, with 10ng/mlIL-1 β and 6.25 μ g/ml~
Row CCK-8 is tested after the anoectochilus roxburghii glycosides of 50 μ g/ml concentration are handled cartilage cell 24 hours, to show that anoectochilus roxburghii glycosides make IL-1 β
The influence of cartilage cell's vigor under.Fig. 2 is the result figure that CCK-8 is tested in embodiment 1.2.CCK-8 experiment display cell
Absorbance value at 450nm, absorption values are higher, show that cell activity is stronger.Standard is carried out with the absorbance of control group
Change, the results show that IL-1 β reduces cartilage cell's vigor, the 6.25 μ g/ml anoectochilus roxburghii glycosides dose dependents of μ g/ml~25 mitigate IL-
Chondrocyte injury caused by 1 β, 50 μ g/ml anoectochilus roxburghii glycosides can aggravate cartilage damage.
1.3 is small using the IL-1 β of 10ng/ml concentration and the 6.25 μ g/ml anoectochilus roxburghii glycosides of μ g/ml~25 processing cartilage cell 24
Shi Houyong AnnexinV/PI agents on cellular apoptosis situation is analyzed.Fig. 3 shows anoectochilus roxburghii glycosides under IL-1 β effect
The influence of articular chondrocyte apoptosis；Wherein, A figure is flow cytometer showed result figure, and every figure is divided into upper left, lower-left, upper right, bottom right four
A quadrant.Right upper quadrant shows the cell of early apoptosis, and right lower quadrant is the cell of late apoptic.When counting apoptosis rate,
Upper right, the ratio of right lower quadrant is added together.B figure is the statistical result for A figure.The results show that IL-1 β promotes cartilage thin
Born of the same parents' apoptosis, the 6.25 μ g/ml anoectochilus roxburghii glycosides dose dependents of μ g/ml~25 reduce the beta induced articular chondrocyte apoptosis of IL-1.
2 anoectochilus roxburghii glycosides indirect protection cartilage cell of embodiment
2.1. anoectochilus roxburghii glycosides adjust macrophage polarization
2.1.1 by RAW264.7 kind in confocal ware, 5*10^5 cell of every ware.LPS 100ng/ml and IFN-γ
20ng/ml is stimulated RAW264.7 24 hours and is obtained M1 type macrophage, and common with the 6.25 μ g/ml anoectochilus roxburghii glycosides of μ g/ml~25
Processing.IL-420ng/ml is stimulated RAW264.7 24 hours and is obtained M2 type macrophage.Fig. 4 shows that anoectochilus roxburghii glycosides are thin to macrophage
The polarized influence of born of the same parents；Wherein, A figure is thin with immunofluorescence method analysis M1 type macrophage mark CD16/32 and M2 type macrophage
Born of the same parents indicate CD206 expression, and for A figure the result shows that anoectochilus roxburghii glycosides lower M1 Macrophage Surface molecule CD16/32, up-regulation M2 is huge
Phagocyte surface molecular CD206.B figure is stream type cell analyzer analysis M1/M2 macrophage ratio, and every figure is divided into four
Quadrant, left upper quadrant represent the CD16/32 positive i.e. M1 type macrophage, and it is thin that right lower quadrant represents the CD206 positive i.e. M2 type macrophage
Born of the same parents, C figure are the statistical charts for B figure, it is seen that the ratio of anoectochilus roxburghii glycosides reduction M1 macrophage.The results show that under anoectochilus roxburghii glycosides
M1 macrophage ratio is adjusted, the ratio of M2 macrophage is raised.
2.1.2 by RAW264.7 cell kind in 6 orifice plates, 5*10^5, every hole cell.With LPS 100ng/ml+IFN- γ
After 20ng/ml and the anoectochilus roxburghii glycosides of the 6.25 μ g/ml concentration of μ g/ml~50 stimulate 24 hours, the albumen for collecting cell is carried out
The GAP-associated protein GAP of Western blot detection NF- κ B and MAPK access.It is in after the developed instrument development of the result of Western blot
Offer the band for grey, in Fig. 5, A figure is the Western blot result figure of the key protein of NF- κ B access, the histogram of B figure
It is for the statistics of band gray value in A figure, gray value is higher to show that expressing quantity is higher.The p-IKK- α/β of upstream, IKK-
α and IKK- β, p-IKB α, the IKB α, p-p65 and p65 in downstream are the key proteins of NF- κ B access, and Fig. 5 can be seen that roxburgh anoectochilus terminal bud
Glycosides has no effect on the gray value of p-IKK, and significantly reduces the gray value of downstream p-IKB α and p-p65 band, illustrates anoectochilus roxburghii glycosides
The expression of NF- κ B signal circuit upstream albumen p-IKK albumen is not influenced, and downstream p-IKB α and p-p65 is inhibited to express.p-JNK/
JNK, p-ERK/ERK, p-p38/p38 are the key proteins of MAPK access, and C figure is the key protein of MAPK access in Fig. 5
Westerrn blot result figure, D are the statistics histograms for band gray value in C figure.In figure the result shows that, anoectochilus roxburghii glycosides
Significantly suppress the expression of p-JNK, p-ERK and p-p38.
2.2 anoectochilus roxburghii glycosides inhibit macrophage M1 polarization, promote M2 polarization, and then protect cartilage cell
2.2.1 by RAW264.7 cell kind in 6 orifice plates, 5*10^5, every hole cell is used after giving different stimulated
Trizol collects the RNA of cell and carries out RT-qPCR.RT-qPCR is the polymerase chain amplification using RNA reverse transcription and cDNA
The technology combined can expand the DNA of particular sequence by specific primer, and the yield of DNA can reflect the gene
Initial expression level.Fig. 6 is using after RT-qPCR detection anoectochilus roxburghii glycosides processing, and different inflammatory factors are relative to control group
Ratio, ratio is higher to illustrate that gene expression dose is higher.The results show that M1 type macrophage IL-1 β, IL-6, TNF-α, iNOS,
The ratio of IL-12a and IL-12b significantly increases, and these ratios can be significantly reduced in anoectochilus roxburghii glycosides, illustrates that anoectochilus roxburghii glycosides press down
Macrophage inflammatory factor IL-1 β, IL-6, TNF-α, iNOS, the expression of IL-12a and IL-12b gene are made.These inflammation because
Son can aggravate arthritic progress with damaged cartilage, therefore anoectochilus roxburghii glycosides are by inhibiting NF- κ B and MAPK signal path downstream
Inflammatory factor expression alleviates damage of the inflammatory factor to cartilage cell indirectly.
2.2.2M1 after cultivating 24 hours with the 6.25 μ g/ml anoectochilus roxburghii glycosides of μ g/ml~25 or M2, supernatant, PBS cleaning three are gone
Time, serum free medium is added and continues culture 24 hours, collects its conditioned medium, is centrifuged, collects supernatant.Cartilage cell's kind
In in 96 orifice plates, 8000, every hole cell.Corresponding conditioned medium is small by different proportion dilution post-processing cartilage cell 24
Shi Houhang CCK-8 experiment, records the absorbance value (OD450) of 450nm.Fig. 7 is CCK-8 experimental result, and cell is at 450nm
Absorbance value, numerical value is bigger to illustrate that cell activity is better.Wherein, 0,1: 8,1: 4,1: 2,1 is macrophage conditioned media pair
Cartilage cell is stimulated using normal incubation medium in the diluted multiple of normal incubation medium, 0,1 uses undiluted macrophage condition
Culture medium stimulates cartilage cell.CCK-8 the experimental results showed that the conditioned medium after anoectochilus roxburghii glycosides stimulating expression of macrophage to soft
The influence of osteocyte vigor.The results show that M1 type macrophage conditioned media significantly presses down under 1: 2 or undiluted situation
Cartilage cell's vigor processed, then dose dependent redemption is soft for the another conditioned medium for adding the 6.25 μ g/ml anoectochilus roxburghii glycosides of μ g/ml~25
Osteocyte vigor.After illustrating that anoectochilus roxburghii glycosides inhibit NF- κ B and MAPK signal path, downstream inflammatory factor expression is influenced.
3 anoectochilus roxburghii glycosides of embodiment mitigate the regression of rat cartilage of osteoarthritis, slow down joint space stenosis
20 Sprague-Dawley rats (200 ± 20g of weight) are randomly divided into 5 groups (4/cage).Group 1 cuts knee joint
Direct suture is the control group (Ctrl) of this experiment afterwards；Group 2 cuts knee joint and cuts anterior cruciate ligament (ACLT)；Group
500 μ L anoectochilus roxburghii glycosides (2.5mg/kg/bw) are injected intraperitoneally in 3ACLT+；500 μ L anoectochilus roxburghii glycosides (5mg/ are injected intraperitoneally in group 4ACLT+
kg/bw)；500 μ L anoectochilus roxburghii glycosides (10mg/kg/bw) are injected intraperitoneally in group 5ACLT+.Row puts to death rat after drug therapy 4 weeks, and takes
The knee joint of rat carries out X-ray inspection out, row HE and the fast green dyeing of sarranine after paraffin embedding of then drawing materials.In Fig. 8, A figure
It is the X-ray piece of rat knee joints, picture shows that control group has apparent joint space, and ACLT processing posterior joint gap is narrow
Narrow, after anoectochilus roxburghii glycosides, joint space obtains a degree of recovery, and it is narrow to show that anoectochilus roxburghii glycosides slow down joint space
Degree.B figure is the HE colored graph to knee joint slice, and C figure is fast green (the Safranin O-fast of sarranine to knee joint slice
Green) colored graph, control group has complete articular surface and articular cartilage as the result is shown, and ACLT destroys articular cartilage and pass
The integrality of nodal section, but damaged and alleviated using anoectochilus roxburghii glycosides articular cartilage of immobilized.Fig. 8 general description anoectochilus roxburghii glycosides pass through
Slow down joint space stenosis, mitigate rabbit cartilage damage and treated osteoarthritis.
It is tested by above series of, demonstrating anoectochilus roxburghii glycosides can reduce damage of the inflammatory factor IL-1 β to cartilage cell,
Directly protect cartilage cell；Can also targeted inhibition control the polarized NF- κ B signal access of macrophage, lower the pole macrophage M1
Change level, promote M2 polarization level, to reduce the release of NF- κ B relevant inflammatory factors, protects cartilage cell in vivo and in vitro.This
Outside, cartilage cell is stimulated with macrophage conditioned media, it is thin that discovery anoectochilus roxburghii glycosides can reduce cartilage caused by conditioned medium
Born of the same parents' vigor inhibits and apoptosis, i.e. the inhibition of cartilage cell's vigor and apoptosis caused by the inflammatory microenvironment by mitigating osteoarthritis,
Play the role of indirect protection cartilage, to treat and slow down osteoarthritis.
The above are the descriptions to the embodiment of the present invention to keep this field special by the foregoing description of the disclosed embodiments
Industry technical staff can be realized or using the present invention.Various modifications to these embodiments carry out those skilled in the art
Saying will be apparent, and the general principles defined herein can be the case where not departing from the spirit or scope of the present invention
Under, it realizes in other embodiments.Therefore, the present invention will not be limited to the embodiments shown herein, but to accord with
Close the widest scope consistent with the principles and novel features disclosed herein.
Claims (9)
1. application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug.
2. application of the anoectochilus roxburghii glycosides as described in claim 1 in osteoarthritis treatment drug, which is characterized in that anoectochilus roxburghii glycosides
For treating the osteoarthritis because of caused by cartilage damage.
3. application of the anoectochilus roxburghii glycosides as claimed in claim 2 in osteoarthritis treatment drug, which is characterized in that anoectochilus roxburghii glycosides
Osteoarthritis caused by cartilage damage caused by for treating because of macrophage M1 polarization.
4. application of the anoectochilus roxburghii glycosides as claimed in claim 3 in osteoarthritis treatment drug, which is characterized in that anoectochilus roxburghii glycosides
By inhibiting macrophage M1 polarization, directly protection cartilage cell, play a role in treatment osteoarthritis.
5. application of the anoectochilus roxburghii glycosides as claimed in claim 3 in osteoarthritis treatment drug, which is characterized in that anoectochilus roxburghii glycosides
By the polarized NF- κ B signal access of targeted inhibition macrophage, macrophage M1 polarization level is lowered, promotes M2 polarized water
It is flat, and then the release of NF- κ B relevant inflammatory factors is reduced, cartilage cell is protected, to slow down and treat osteoarthritis.
6. application of the anoectochilus roxburghii glycosides as claimed in claim 2 in osteoarthritis treatment drug, which is characterized in that anoectochilus roxburghii glycosides
For slowing down and treating because inflammatory factor IL-1 β is to osteoarthritis caused by the damage of cartilage cell.
7. application of the anoectochilus roxburghii glycosides as claimed in claim 6 in osteoarthritis treatment drug, which is characterized in that anoectochilus roxburghii glycosides
By mitigating damage of the inflammatory factor IL-1 β to cartilage cell, directly protection cartilage cell, to slow down and treat Bones and joints
It is scorching.
8. application of the anoectochilus roxburghii glycosides as claimed in claim 2 in osteoarthritis treatment drug, which is characterized in that anoectochilus roxburghii glycosides
By mitigating the inhibition of cartilage cell's vigor caused by macrophage conditioned media and apoptosis, the work of indirect protection cartilage is played
With.
9. application of the anoectochilus roxburghii glycosides as claimed in claim 2 in osteoarthritis treatment drug, which is characterized in that anoectochilus roxburghii glycosides
Cartilage cell's vigor caused by inflammatory microenvironment by mitigating osteoarthritis inhibits and apoptosis, plays the work of indirect protection cartilage
With to treat and slow down osteoarthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811522812.7A CN109394777A (en) | 2018-12-12 | 2018-12-12 | Application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811522812.7A CN109394777A (en) | 2018-12-12 | 2018-12-12 | Application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109394777A true CN109394777A (en) | 2019-03-01 |
Family
ID=65458943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811522812.7A Pending CN109394777A (en) | 2018-12-12 | 2018-12-12 | Application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109394777A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106929474A (en) * | 2017-03-31 | 2017-07-07 | 北京恒峰铭成生物科技有限公司 | A kind of M2 macrophages derivant |
| CN111920812A (en) * | 2020-07-10 | 2020-11-13 | 深圳市臻质医疗科技有限公司 | Application of calcium channel inhibitor oxyliporine in osteoarthritis |
| CN114634535A (en) * | 2021-12-20 | 2022-06-17 | 嘉文丽（福建）化妆品有限公司 | Separation and purification method of anoectochilus formosanus glycoside and application of anoectochilus formosanus glycoside in soothing cosmetics |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101434625A (en) * | 2008-12-12 | 2009-05-20 | 华中科技大学 | Anoectochilus roxburghii glycosides, derivatives thereof, preparation and use |
| CN106377536A (en) * | 2016-08-16 | 2017-02-08 | 上海交通大学医学院附属第九人民医院 | Applications of kinsenoside in endothelial cell protection and gouty arthritis treatment |
-
2018
- 2018-12-12 CN CN201811522812.7A patent/CN109394777A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101434625A (en) * | 2008-12-12 | 2009-05-20 | 华中科技大学 | Anoectochilus roxburghii glycosides, derivatives thereof, preparation and use |
| CN106377536A (en) * | 2016-08-16 | 2017-02-08 | 上海交通大学医学院附属第九人民医院 | Applications of kinsenoside in endothelial cell protection and gouty arthritis treatment |
Non-Patent Citations (1)
| Title |
|---|
| 李宁: "NF-κB作为骨关节炎的靶向治疗研究进展", 《西安体育学院学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106929474A (en) * | 2017-03-31 | 2017-07-07 | 北京恒峰铭成生物科技有限公司 | A kind of M2 macrophages derivant |
| CN111920812A (en) * | 2020-07-10 | 2020-11-13 | 深圳市臻质医疗科技有限公司 | Application of calcium channel inhibitor oxyliporine in osteoarthritis |
| CN111920812B (en) * | 2020-07-10 | 2022-09-20 | 深圳市臻质医疗科技有限公司 | Application of calcium channel inhibitor oxylipine in osteoarthritis |
| CN114634535A (en) * | 2021-12-20 | 2022-06-17 | 嘉文丽（福建）化妆品有限公司 | Separation and purification method of anoectochilus formosanus glycoside and application of anoectochilus formosanus glycoside in soothing cosmetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Longo et al. | Sympathetic fiber sprouting in inflamed joints and adjacent skin contributes to pain-related behavior in arthritis | |
| Clutterbuck et al. | Interleukin‐1β–Induced Extracellular Matrix Degradation and Glycosaminoglycan Release Is Inhibited by Curcumin in an Explant Model of Cartilage Inflammation | |
| CN109394777A (en) | Application of the anoectochilus roxburghii glycosides in osteoarthritis treatment drug | |
| Miller et al. | Pulsed electromagnetic field (PEMF) treatment reduces expression of genes associated with disc degeneration in human intervertebral disc cells | |
| Wang et al. | Quercetin suppresses apoptosis of chondrocytes induced by IL-1β via inactivation of p38 MAPK signaling pathway | |
| Vliagoftis et al. | Rapidly changing perspectives about mast cells at mucosal surfaces | |
| EP2191836B1 (en) | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent | |
| Sun et al. | Chondroitin sulfate from sturgeon bone ameliorates pain of osteoarthritis induced by monosodium iodoacetate in rats | |
| Hsueh et al. | Therapeutic effect of induced pluripotent stem cell-derived extracellular vesicles in an in vitro and in vivo osteoarthritis model | |
| Gao et al. | Naringin protects against interleukin 1β (IL-1β)-induced human nucleus pulposus cells degeneration via downregulation nuclear factor kappa B (NF-κB) pathway and p53 expression | |
| Yuan et al. | Effect of sea buckthorn protein on the intestinal microbial community in streptozotocin-induced diabetic mice | |
| Xie et al. | Vaccarin promotes endothelial cell proliferation in association with neovascularization in vitro and in vivo | |
| Ezeani et al. | Effects of aqueous and ethanol root extracts of Olax subscopioidea on inflammatory parameters in complete freund’s adjuvant-collagen type II induced arthritic albino rats | |
| WO2024041604A1 (en) | Use of yogurt-derived polypeptide in preparation of drug for delaying telomere shortening and anti-aging drug | |
| Maher et al. | Plasma and synovial fluid concentration of doxycycline following low‐dose, low‐frequency administration, and resultant inhibition of matrix metalloproteinase‐13 from interleukin‐stimulated equine synoviocytes | |
| Xu et al. | Role of thrombospondin-1 and nuclear factor-κb signaling pathways in antiangiogenesis of infantile hemangioma | |
| Li et al. | Expression and interaction of TNF-α and VEGF in chronic stress-induced depressive rats | |
| Zeng et al. | Amygdalin delays cartilage endplate degeneration and improves intervertebral disc degeneration by inhibiting NF-κB signaling pathway and inflammatory response | |
| Wang et al. | Litchi thaumatin-like protein induced the liver inflammation and altered the gut microbiota community structure in mice | |
| Fang et al. | The mechanism of aerobic exercise combined with glucosamine therapy and circUNK in improving knee osteoarthritis in rabbits | |
| WO2021129649A1 (en) | USE OF α-KETOGLUTARATE IN PREPARATION OF DRUG | |
| CN118477064B (en) | Application of baicalein in resisting rhabdovirus of largehead jewfish | |
| CN118178591A (en) | A Chinese medicine composition for preventing and treating knee osteoarthritis and its application | |
| Zhu et al. | Artesunate interfere in modulation of Foxp3 expression in synovial cells in collagen-induced arthritis rats | |
| Shao et al. | Ovalbumin-digested peptides can reverse cyclophosphamide-induced immune dysfunction in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190301 |